Navigation Links
Aethlon Medical Names Rod Kenley President

SAN DIEGO, Oct. 28 /PRNewswire-FirstCall/ -- Aethlon Medical, Inc. (OTC Bulletin Board: AEMD), the pioneer in developing therapeutic filtration devices to address infectious disease and cancer, announced today that it has named Rod Kenley to be President of Aethlon Medical.  Aethlon Chairman and CEO, Jim Joyce, previously also held the title of President.  Mr. Kenley recently joined Aethlon's Board of Directors and will retain his Board seat as an inside director.  



"We are extremely pleased to have Rod become a full-time member of our team," stated Jim Joyce.  "As referenced when he joined our board, Rod has been instrumental in commercializing some of the most important advances in the dialysis industry. He is among the best in industry talent, whose full focus towards our endeavors will immediately impact our business and improve our efficiency in advancing established and future opportunities."

Mr. Kenley has 33 years of experience in healthcare, most of which have been spent in the extracorporeal blood purification arena. Mr. Kenley held several positions at Baxter Healthcare (Travenol) from 1977 through 1990 including International Marketing Manager, Business Unit Manager for Peritoneal and Hemodialysis products, Manager of New Business Development, Director of Worldwide Product Planning, Director of Advanced Product Development, and VP of Electronic Drug Infusion.  During this tenure, he conceived of and managed the launch of several new products that have been highly commercially successful including the HomeChoice peritoneal dialysis cycler.

Mr. Kenley founded Aksys Ltd. in January 1991 to develop and commercialize his concept of a daily home hemodialysis system which was commercially launched in 2002 as the PHD system.  In 2004, Mr. Kenley initiated the development of a second-generation home hemodialysis system in partnership with DEKA Research & Development Corporation in Manchester, New Hampshire.  In 2007, the assets of Aksys Ltd. were acquired by DEKA, where Mr. Kenley was employed prior to joining Aethlon.  

Mr. Kenley is the recipient of over 30 patents and has been a frequent presenter at international symposia regarding the provision of dialysis, the design of dialysis equipment, designing medical equipment according to FDA guidelines as well as lecturing at the Kellogg School of Management at Northwestern University and at other business schools in the area of entrepreneurship.

Mr. Kenley received his Bachelor of Arts degree in Biology and Chemistry from Wabash College, a Masters of Science degree in Molecular Biology from Northwestern University and a Masters of Management from the Kellogg School of Management, also at Northwestern University.

About Aethlon MedicalAt Aethlon Medical, we create revolutionary devices to address infectious disease and cancer. Our devices are designed to be novel platform solutions that fill therapeutic voids or aid in disease diagnosis and monitoring.

Our Hemopurifier® is the first medical device to selectively target the removal of infectious viruses and immunosuppressive proteins from the entire circulatory system. We recently discovered that our Hemopurifier® captures tumor-secreted exosomes that suppress the immune system of those afflicted with cancer. Prior to this discovery, a therapeutic strategy to directly inhibit or reverse the immunosuppressive destruction caused by exosomes did not exist in cancer care. By eliminating this mechanism, we believe our Hemopurifier® can fill an unmet clinical need and provide the benefit of an immune-based therapy without adding drug toxicity or interaction risks to established and emerging treatment strategies.

Human studies have documented the ability of our Hemopurifier® to safely reduce viral load in both Hepatitis-C virus (HCV) and Human Immunodeficiency Virus (HIV) infected patients without the administration of antiviral drugs.  However, our initial clinical and commercialization focus is to establish our Hemopurifier® as an adjunct therapy to enhance the benefit of both infectious disease and cancer treatment regimens. In this regard, we plan to commercialize our Hemopurifier® in India as we advance our clinical strategies in the United States and the European Union.  In vitro studies conducted by government and non-government research institutes have also verified that our Hemopurifier® has broad-spectrum capabilities against bioterror and emerging pandemic threats. These studies have confirmed the capture of Dengue Hemorrhagic Virus, Ebola Hemorrhagic Virus, Lassa Hemorrhagic Virus, West Nile Virus, H5N1 Avian Influenza Virus, 2009 H1N1 Influenza Virus, the reconstructed Spanish Flu of 1918 Virus, and Monkeypox Virus, which serves as a model for human Smallpox infection.

As a therapeutic device, the Hemopurifier® provides us with a pipeline into four significant market opportunities:

  1. Cancer: A treatment candidate to improve patient responsiveness to established cancer therapies by removing immunosuppressive exosomes from circulation.
  2. Hepatitis-C Virus (HCV): As an adjunct therapy to accelerate viral load reduction at the outset of standard of care drug regimens.  
  3. Human Immunodeficiency Virus (HIV):  Provides a potential therapeutic option for HIV-infected individuals to manage disease progression once they become resistant to antiviral drug regimens.
  4. Bioterror and Pandemic Threats:  Represents the most advanced broad-spectrum strategy to address untreatable bioterror and emerging pandemic threats.

The Hemopurifier® is an expansive multi-patented platform technology whose mechanism of action can be leveraged to provide therapeutic, diagnostic, and biomarker discovery solutions. As a therapeutic, the Hemopurifier® is a single-use disposable cartridge designed for implementation within the established infrastructure of dialysis machines and other blood circulatory pumps already located in hospitals and clinics worldwide.

In design, our Hemopurifier® is a selective filtration device containing affinity agents that tightly bind to high-mannose structures unique to the surface of exosomes produced by cancer and glycoproteins residing on the envelope of viruses. These agents are immobilized around approximately 2800 porous hollow fibers that run the interior length of our device. The resulting design provides us the novel ability to separate both exosome and viral targets away from blood cells so they can then be selectively and permanently removed from the circulatory system. In application, blood circulation is established into the Hemopurifier® via a catheter or other blood access device. Once blood flow has been established, treatment benefit is immediate as the entire circulatory system can pass through the Hemopurifier® in as little as 15 minutes.

Our wholly owned subsidiary, Exosome Sciences, Inc. (ESI), is focused on the development of exosome-targeted products and services that improve cancer diagnosis, provide post-treatment cancer surveillance, and aid in the discovery of biomarkers that allow doctors to optimize patient therapy. Additional information regarding Aethlon Medical and Exosome Sciences can be accessed online at A. JoyceChairman, CEO858.459.7800 x301jj@aethlonmedical.comJohn P. SalvadorDirector, Communications & Investor Relations858.459.7800 x307jps@aethlonmedical.comJon CunninghamRedChip Companies, Inc.800.733.2447

SOURCE Aethlon Medical, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Aethlon Medical Announces Appointment of Rod Kenley to Its Board of Directors
2. Aethlon Medical Engages Fabiani & Company to Advance U.S. Government Partnerships
3. Aethlon Medical Reestablishes Biodefense Programs
4. Aethlon Medical to Present at Rodman & Renshaw Annual Global Investment Conference
5. Aethlon Medical Announces Approval of Hepatitis C Virus (HCV) Treatment Program
6. Aethlon Medical Announces Expansion of Hepatitis C Virus (HCV) Treatment Programs
7. Aethlon Medical Discloses Live Webcast of Todays BIOCOM Presentation
8. Aethlon Medical Releases Medical Device Data Against the H1N1 Swine Flu Virus
9. Aethlon Medical Announces Presentation of Hepatitis-C (HCV) Clinical Data at 42nd Annual American Society of Nephrology (ASN) Conference
10. Aethlon Medical to Present at the 2009 RedChip Small-Cap Investor Conference on June 16, 2009
11. Essential Pharmaceuticals Acquires Exclusive Worldwide Rights to Family of Cell Media Products from Lifeblood Medical
Post Your Comments:
(Date:11/30/2015)... --  Royal Philips  (NYSE: PHG ; AEX: ... a fully integrated, consultative approach to enhance radiology ... management approaches that combine imaging systems, services, informatics ... delivery and reduce costs. Making its debut at ... Annual Meeting (RSNA) in Chicago ...
(Date:11/30/2015)... CHICAGO , Nov. 30, 2015 Nautilus ... next-generation Radiology Image Management platform ( ). The ... was announced from RSNA 2015 (Radiology Society North America) ... Radiology conference in the U.S. --> ... radiology platform that enables access to radiology studies worldwide ...
(Date:11/30/2015)... (HK$,000)For the Six Months Ended 30 September 2015 2014RestatedChange%Turnover 545,575 , 518,852 ... , 384,242 , 9.8 Hospital ... , (18.3) Medical Insurance Administration Service Income , ... Medical Devices and Accessories Sales , 89,645 , ... , 2,822 , 2,917 , ...
Breaking Medicine Technology:
(Date:11/30/2015)... , ... November 30, 2015 , ... The world of ... harvesting and follicular unit extraction. These techniques and procedures have been in use for ... from hair loss. While Dr. Parsa Mohebi, M.D. has utilized many of these methods ...
(Date:11/30/2015)... Battle Creek, Michigan (PRWEB) , ... November 30, 2015 , ... ... Creek, MI, the American Cancer Society held an annual fundraising event, a 5K walk ... Recovery, a holistic treatment center for substance abuse which is also located in Battle ...
(Date:11/30/2015)... ... November 30, 2015 , ... The presidential race normally deals with political issues ... it a national news story when Donald Trump makes disparaging remarks about Hillary Clinton’s ... more than anyone wants to admit when it comes to how people are viewed ...
(Date:11/30/2015)... Angeles, CA (PRWEB) , ... November 30, 2015 , ... ... star Jessie James Decker made a brave but slightly unusual choice to show her ... returning to her pre-pregnancy form may have been pre-mature. Saying that she didn’t “want ...
(Date:11/30/2015)... ... ... According to Los Angeles bariatric surgeon Michael Feiz, M.D., F.A.C.S., many of ... hunger, but instead by a hormone called ghrelin which (often prematurely) signals to ... aware that weight loss surgery can help patients lose weight by restricting the capacity ...
Breaking Medicine News(10 mins):